2019 China BioMed Innovation and Investment Conference was held successfully on Sep 21-23 in Suzhou China, the world’s four well-known Exchanges (Hong Kong, Nasdaq, London and Shanghai Stock Exchanges), top-scientists in immunotherapy gathered here to discuss the financing policies of pharmaceutical innovation companies in the world’s leading financing platforms, and help domestic biopharmaceutical companies find suitable cross-border financing channels to promote the innovation and transformation of China's pharmaceutical industry.
At the “Non-listed Company Roadshow” sessions on Sep 22, Mr Gang Xie, Secretary of the Board of Directors of Jiuzhang Biothech, made a special presentation with the topic “Chlorogenic acid for injection----class 1 natural small molecule tumor immunedrug”. The presentation was reviewed the phase I clinical trial of chlorogenic acid for injection, reported the progress of phase II clinical trial in GBM, combined the characteristics of the project, and made a conclusion of investment highlights. The report received enthusiastic attention from the guests and investment companies.
Chlorogenic acid for injection, developed by Jiuzhang Biotech, was the first-in-class natural small molecule immune-metabolism antitumor drug with the clear target, broad antitumor spectrum. By now, this project is in the progress of phase II/III clinical trial in GBM.